These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071 [TBL] [Abstract][Full Text] [Related]
44. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. Powers B; Greene L; Balfe LM J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101 [TBL] [Abstract][Full Text] [Related]
45. The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients - a cross-sectional prospective observational clinical study. Heleniak Z; Illersperger S; Brakemeier S; Bach P; Dębska-Ślizień A; Budde K; Halleck F Acta Biochim Pol; 2020 Dec; 67(4):613-622. PubMed ID: 33332078 [TBL] [Abstract][Full Text] [Related]
46. A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs. Hyman DA; Siebert VR; Birnbaum GD; Alam M; Birnbaum Y Cardiovasc Drugs Ther; 2020 Apr; 34(2):215-221. PubMed ID: 32219664 [TBL] [Abstract][Full Text] [Related]
47. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions. Tylicki L; Lizakowski S; Rutkowski B J Nephrol; 2012; 25(6):900-10. PubMed ID: 22684647 [TBL] [Abstract][Full Text] [Related]
48. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093 [TBL] [Abstract][Full Text] [Related]
49. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000 [TBL] [Abstract][Full Text] [Related]
50. ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy. Umruddin Z; Moe K; Superdock K J Nephrol; 2012; 25(5):776-81. PubMed ID: 22322819 [TBL] [Abstract][Full Text] [Related]
51. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis. Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289 [TBL] [Abstract][Full Text] [Related]
52. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. Kunutsor SK; Blom AW; Whitehouse MR; Kehoe PG; Laukkanen JA Eur J Epidemiol; 2017 Nov; 32(11):947-959. PubMed ID: 28752198 [TBL] [Abstract][Full Text] [Related]
53. Renin-angiotensin system blockade does not attenuate abdominal aortic aneurysm growth, rupture rate, or perioperative mortality after elective repair. Salata K; Syed M; Hussain MA; Eikelboom R; de Mestral C; Verma S; Al-Omran M J Vasc Surg; 2018 Feb; 67(2):629-636.e2. PubMed ID: 29175038 [TBL] [Abstract][Full Text] [Related]
54. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review. Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005 [TBL] [Abstract][Full Text] [Related]
55. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used? Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L Nephron; 2019; 143(2):100-107. PubMed ID: 31203280 [TBL] [Abstract][Full Text] [Related]
56. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy? Werner C; Pöss J; Böhm M Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830 [TBL] [Abstract][Full Text] [Related]
57. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. Ruiz-Hurtado G; Ruilope LM Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982 [TBL] [Abstract][Full Text] [Related]